Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors
Status:
Recruiting
Trial end date:
2024-04-01
Target enrollment:
Participant gender:
Summary
In this study, response to treatment and (progression free and overall) survival will be
described and safety events of ivosidenib in combination with nivolumab will be summarized in
patients with advanced solid tumors (nonresectable or metastatic) or enhancing gliomas.
Phase:
Phase 2
Details
Lead Sponsor:
Jason J. Luke, MD Jason Luke
Collaborators:
Agios Pharmaceuticals, Inc. Bristol-Myers Squibb Bristol-Myers Squibb (BMS)